Compare Mesoblast Limited (MESO) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs PulteGroup, Inc. — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while PulteGroup, Inc. trades at $123.59 (market cap $23.46B). The key difference: PulteGroup, Inc. is far larger — about 10.8× Mesoblast Limited's market cap, and PulteGroup, Inc. pays a 0.84% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PHM | |
|---|---|---|
Market Cap | $2.17B | $23.46B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $142.56 |
52-Week Low | $12.88 | $108.65 |
Enterprise Value | $2.17B | $23.42B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
PulteGroup (PHM) trades at $123.12, down 2.35% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows solid fundamentals with a P/E of 12.19, net income margin of 12.14%, and positive cash flow trends, though recent earnings missed expectations in two of the last three quarters. Recent news highlights mixed investor sentiment amid mortgage rate concerns and new community developments, with a dividend payment scheduled for July 2, 2026.
Outlook is cautiously optimistic with a consensus price target of $146.50, implying 19% upside, supported by strong institutional holdings and a GF Score of 93. Key risks include high mortgage rates pressuring margins and volatile housing demand. The stock's current level near the analyst low target of $123.00 suggests potential support, but earnings performance in the upcoming Q2 report will be critical for momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
